The Osteoarthritis Initiative aims to identify people at risk for OA and monitor disease progression using biological markers. The study will enroll 5,000 adults over five years, collecting data on joint pain, limited movement, and cartilage loss.
A new study published in the New England Journal of Medicine found that people with lupus are more likely to develop fatty deposits in their arteries, accelerating atherosclerosis. The risk is higher in patients who have had the disease longer and those who have used less immunosuppressive treatment.
Researchers found that lupus patients' autoantibodies accumulated in the blood in a predictable pattern before diagnosis, slowing down after therapy. The study's findings may help identify and monitor people at risk of developing autoimmune diseases like lupus.
NIAMS researchers collaborated with Pfizer to develop and test a new immunosuppressant drug, CP-690,550, which targets the immune system without causing toxic side effects. The study showed promising results in mice and monkeys, suggesting potential for treating autoimmune diseases such as lupus and rheumatoid arthritis.
Researchers at three new NIH-funded centers are working on developing gene and stem cell therapies to treat Duchenne muscular dystrophy. The centers will study various aspects of gene therapy, including the delivery and engraftment of muscle stem cells into diseased heart tissue.
Two studies found that combining parathyroid hormone (PTH) and alendronate increases bone mineral density (BMD) at least as well as or better than single drug treatment. Further studies are needed to determine the optimal effects of these drugs, particularly through sequential or cyclic therapy.
Researchers have discovered a genetic signature, known as the IFN expression signature, associated with severe lupus symptoms. This signature is linked to interferon activity and has implications for developing new therapies to block IFN pathways in patients with severe lupus.
The National Institute of Arthritis and Musculoskeletal and Skin Diseases has awarded five new grants to researchers studying stem cells and their potential in treating various musculoskeletal diseases. These studies aim to investigate growth factors, muscle regeneration, connective tissue repair, bone disease treatment, and the develo...
New studies aim to improve diagnosis and treatment for patients with Neuropsychiatric-SLE, a major cause of death among people with lupus. Researchers will investigate the underlying causes of NP-SLE using new tools and approaches.
A study comparing limb reconstruction and amputation after trauma found that patients undergoing both procedures experienced similar functional recoveries, with 53% returning to work within two years. Despite medical advancements, those with amputations had higher rates of rehospitalization for complications.
The National Institutes of Health's NIAMS has funded eight research projects to better understand and treat heritable disorders of connective tissue. These conditions, such as osteogenesis imperfecta and Ehlers-Danlos syndrome, affect millions of Americans and have few effective treatments.
A large multicenter clinical trial will randomly assign patients with tibial fractures to either reaming or non-reaming surgical groups. Surgeons will assess participants at six weeks, three months, and one year to determine the success of the operation.
Researchers have found that deacetylase inhibitors enhance muscle gene expression and formation in human and mouse myoblasts. This discovery may lead to methods to induce muscle growth, regeneration, and repair in adults with muscular dystrophy.
The Osteoarthritis Initiative will recruit 5,000 participants aged 50+ at high risk for knee osteoarthritis. The project aims to establish a natural history database for osteoarthritis, allowing researchers to identify potential new disease targets and develop tools for understanding disease progression.
Muscle stem cells have shown potential in treating muscular dystrophy by differentiating into other cell types and resisting rejection, overcoming major obstacles such as low survival rates and immune system rejection. The study's findings could lead to more effective treatments for MD and other muscle-related diseases.
A new mouse model has shown promise in treating muscular dystrophy by increasing muscle mass and regeneration, reducing muscle cell death. The combination of better muscle regeneration and less muscle wasting could lead to improved muscle capacity over time.
Researchers will study cellular changes, immune responses, and collagen production to develop more effective treatments for scleroderma. The NIH grants will complement existing investments in scleroderma research and bring scientists closer to finding treatments for this disease.
Researchers are studying the molecular pathophysiology of FSHD using genome-wide approaches and developing animal models to understand the disease. The goal is to gain insight into the cellular and molecular processes leading to neuromuscular system dysfunction in FSHD patients.
Researchers have discovered that antibodies attacking DNA in people with lupus can also target molecules controlling glutamate activity, leading to neuron death and possible cognitive symptoms. This finding suggests a potential pathway for neurological complications and may lead to new therapeutic options.
A public-private partnership has been launched to combat osteoarthritis, a chronic disease affecting millions of Americans. The Osteoarthritis Initiative will provide critical funding and resources for clinical research centers to establish natural history databases and biospecimen repositories.
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has established a national family registry for scleroderma research. The registry will study families with one or multiple cases of the disease to identify genetic factors, environmental triggers, and susceptibility genes.
A major review reveals osteoarthritis is a complex disease, but outlines new approaches to understanding, preventing, and treating the condition. The study emphasizes the importance of a healthy lifestyle, including exercise and weight management, in reducing disability and slowing disease progression.
Two new research studies have shown significant promise for reducing joint damage in rheumatoid arthritis, with a combination of infliximab and methotrexate halting progression and improving symptoms in patients. Etanercept also demonstrates efficacy in slowing joint damage and decreasing symptoms.
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has awarded five new grants to support research on osteogenesis imperfecta. These grants will focus on developing treatments, such as gene therapies and drug treatments, to improve diagnosis and treatment options for people with OI.
A new study found that Staphylococcus aureus produces a toxin that breaks down the protein Desmoglein 1, causing blistering and skin cell adhesion loss. The findings provide insight into the bacterial mechanism of impetigo infection and spread.
A systematic analysis of clinical trials on glucosamine and chondroitin sulfate for treating osteoarthritis has shown mixed results, with potential benefits for symptom relief but methodological flaws and biases. The study recommends additional rigorous independent studies to determine true efficacy and usefulness.
A clinical trial of Enbrel in children with polyarticular juvenile rheumatoid arthritis found significant improvement in joint pain, stiffness, and inflammation. The drug was well-tolerated, with a 74% response rate among treated patients.
The National Institute of Arthritis and Musculoskeletal and Skin Diseases has awarded nearly $4 million for new projects on autoimmune diseases. These projects enhance the NIAMS' commitment in this area, focusing on nine conditions that affect almost every human organ system.
A new NIAMS-funded study will enroll 5,700 men aged 65+ to investigate the relationship between bone mass, structure, lifestyle, and fractures. The research aims to determine if high bone mass increases the risk of prostate cancer.
The consortium aims to collect medical information and genetic material from 400 families nationwide with AS to identify additional genes associated with its pathogenesis. Researchers will conduct genome-wide searches and map genes linked to AS outside of the MHC.
Researchers will compare surgical and nonsurgical treatments for herniated discs, spinal stenosis, and degenerative spondylolisthesis in a 5-year study. The study aims to determine the relative effectiveness of these treatment approaches in improving health-related quality of life and reducing resource use.
A nationwide effort to find genes that determine susceptibility to rheumatoid arthritis has been launched, with researchers collecting medical information and genetic material from 1,000 families. The project aims to identify genetic regions shared by affected siblings, which may contain genes involved in the disease.
Researchers have identified the gene responsible for Familial Mediterranean Fever (FMF), an inherited disease characterized by recurring fevers, abdominal pain, and inflammation. The discovery of the pyrin protein mutations may lead to a simple diagnostic blood test and improved treatments for FMF.